Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne (NASDAQ: TECH) announced advancements in its spatial biology portfolio, featuring the RNAscope™ ISH technology and Lunaphore COMET™ platforms. These innovations enable simultaneous detection of RNA and protein biomarkers on the same tissue section, bridging translational research and clinical applications.

The company will showcase these technologies at the National Society of Histotechnology Convention (September 26-30), featuring presentations on RNAscope's application in B-cell clonality assessment and COMET's capabilities in lymphoid malignancy profiling using a 21-plex seqIF™ panel. Bio-Techne is also advancing its partnership with Leica Biosystems, co-hosting a reception to demonstrate RNAscope assays on Leica BOND platforms.

Bio-Techne (NASDAQ: TECH) has released its 2025 Corporate Sustainability Report, highlighting significant progress in environmental stewardship and innovation. The company achieved a notable 40% reduction in Scope 1 and 2 emissions through renewable electricity adoption at its Minneapolis headquarters.

Under CEO Kim Kelderman's leadership, Bio-Techne has committed to setting science-based GHG reduction targets for validation by SBTi in 2026. The company continues to advance breakthroughs in various diseases while implementing enhanced governance measures, including new Board oversight of AI and completion of climate assessments.

The report emphasizes Bio-Techne's focus on sustainable innovation across its life sciences portfolio, particularly in cell therapy, proteomic instruments, and precision diagnostics.

CONMED Corporation (NYSE: CNMD) has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman currently serves as President, CEO, and Board member of Bio-Techne (NASDAQ: TECH) since February 2024.

Kelderman brings extensive experience in life sciences, having previously held leadership positions at Thermo Fisher Scientific, where he led multiple businesses and managed the Platforms and Content of the Genetic Sciences Division. Prior to that, he served as Senior Segment Leader at Becton Dickinson, overseeing the global Blood Tubes "Vacutainer" business.

ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, has awarded eight G-Rex Grants totaling nearly $2 million to California Institute for Regenerative Medicine (CIRM) Manufacturing Network program recipients. The grants support cell and gene therapy (CGT) manufacturing advancement in California.

The grants, ranging from $125,000 to $300,000, were awarded to prestigious institutions including UC San Diego, City of Hope, Stanford Medicine, USC/CHLA, UC Davis, UCSF, UCLA, and Cedars Sinai. These grants are part of ScaleReady's $40 million initiative to advance CGT development and manufacturing.

Recipients will receive exclusive support from ScaleReady's consortium of G-Rex Grant Partners, offering expertise in cGMP manufacturing, quality control, regulatory affairs, and CGT business operations.

Bio-Techne (NASDAQ: TECH) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference on September 3 at 10:15 AM EDT, the Baird Global Healthcare Conference on September 9 at 9:05 AM EDT, and the Morgan Stanley Global Healthcare Conference on September 10 at 10:45 AM EDT.

Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website under the IR Calendar page.

ScaleReady (NYSE:TECH) has awarded a $300,000 G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory to develop a modular CAR T-cell manufacturing platform. The grant will support optimization of key CAR-T cell manufacturing steps through Design of Experiments (DoE) evaluation.

The Gates Institute will receive early access to CellReady's G-CAR-T™, a standardized CAR-T drug product manufacturing operation. ScaleReady's G-Rex Grant Program has authorized over $40M of products to grant recipients to advance cell and gene therapy development and manufacturing.

Additionally, ScaleReady announced a new free program called LEAN Cell & Gene™, launched in partnership with Hanson Wade, aimed at improving efficiency in CGT manufacturing.

Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2025. The dividend will be payable on August 29, 2025, to shareholders of record as of August 18, 2025.

The company, a global life sciences leader providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of $1.2 billion in fiscal 2025 and employs approximately 3,100 people worldwide. Bio-Techne's products support scientific research into biological processes, disease progression, drug discovery, and clinical diagnostics.

Bio-Techne (NASDAQ: TECH) reported its Q4 and full-year fiscal 2025 results, with Q4 organic revenue growing 3% (4% reported) to $317.0 million. Full-year organic revenue increased 5% to $1.2 billion. The company reported Q4 GAAP EPS of $(0.11) versus $0.25 year-over-year, while adjusted EPS improved to $0.53 from $0.49.

The Protein Sciences segment showed strong performance with 4% organic growth (6% reported) in Q4. Notably, Bio-Techne announced the divestiture of its Exosome Diagnostics business, resulting in an $83.1 million impairment loss. The company's Q4 adjusted operating margin was 32.0%, down from 33.5% in the previous year, impacted by unfavorable product mix.

Bio-Techne (NASDAQ: TECH) has announced the divestiture of its Exosome Diagnostics business to Mdxhealth SA. The deal includes the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory, and related assets. Bio-Techne will maintain access to the proprietary exosome-based technology for kit development in its precision diagnostics segment.

Under the agreement terms, Bio-Techne will receive $5 million in MDXH stock plus future considerations. The transaction is expected to close in Q1 of Bio-Techne's fiscal 2026. The strategic move aims to strengthen Bio-Techne's focus on developing high-value products for life science research and clinical diagnostics markets while improving its operating margin profile.